Oxurion N.V. (0G99.L) LSE
Currency In EUR
- General
- Statistics
- Historical Data
- Profile
- Financials
Oxurion N.V.
Sector
Healthcare
Industry
Medical - Pharmaceuticals
Employees
11
First IPO Date
August 06, 2008
Key Executives
| Name | Title | Pay | Year Born |
| Pascal Ghoson | Chief Executive Officer, Chief Financial Officer & Executive Director | 330,000 | 1989 |
Description
Oxurion N.V. is a biopharmaceutical enterprise dedicated to the research, development, and marketing of innovative treatments for ocular diseases, operating both within Belgium and across international markets. Its primary commercialized therapy is JETREA, prescribed for vitreomacular adhesion and vitreomacular traction. Beyond this, Oxurion's clinical pipeline includes two promising compounds in Phase II trials for diabetic macular edema (DME): THR-149, which functions as a plasma kallikrein inhibitor, and THR-687, an integrin antagonist. The company also fosters collaborative relationships with Bicycle Therapeutics, INC Research, and Galapagos NV. Founded in 1991, this Leuven, Belgium-headquartered firm adopted its current name, Oxurion N.V., in September 2018, having previously operated as ThromboGenics NV.
